dehydroepiandrosterone has been researched along with Sex Disorders in 39 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Topical interventions (vaginal gels or creams) were able to alleviate vaginal dryness and dyspareunia, with intravaginal dehydroepiandrosterone (DHEA) (6." | 5.22 | Efficacy of interventions to manage sexual dysfunction in women with cancer: a systematic review. ( Febrina, F; Marino, JL; Peate, M; Triyoga, IF; White, M, 2022) |
| " Vaginal estrogen preparations with the lowest systemic absorption rate may be preferred in women with history of breast cancer and severe vaginal atrophy." | 2.48 | Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. ( Bradshaw, K; Carr, BR; Tan, O, 2012) |
| " Moreover; a low dose treatment with a minimised systemic absorption rate may be considered in women with a history of breast cancer and associated severe vulvovaginal atrophy." | 2.48 | [Local estrogen therapy--clinical implications--2012 update]. ( Bartuzi, A; Kokot-Kierepa, M; Kulik-Rechberger, B; Rechberger, T, 2012) |
| "Dehydroepiandrosterone (DHEA) is an abundant circulating androgen precursor preferentially produced by the adrenal glands." | 2.43 | Dehydroepiandrosterone therapy as female androgen replacement. ( Guay, A; Saltzman, E, 2006) |
| " This paper includes practical considerations on dosage to be used, contraindications and follow-up." | 2.42 | Androgen therapy with dehydroepiandrosterone. ( Buvat, J, 2003) |
| "Polycystic ovarian syndrome and hypogonadotropic hypogonadism occurred significantly more often in women with TLE than in the general female population." | 1.27 | Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. ( Geschwind, N; Herzog, AG; Schomer, DL; Seibel, MM; Vaitukaitis, JL, 1986) |
| "The effect of long-term administration of digoxin on sexual dysfunction was investigated in correlation to plasma androgens level." | 1.27 | The effect of long-term administration of digoxin on plasma androgens and sexual dysfunction. ( Aygen, M; Kaufman, H; Lidor, Y; Neri, A; Zukerman, Z, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (15.38) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 11 (28.21) | 29.6817 |
| 2010's | 19 (48.72) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Febrina, F | 1 |
| Triyoga, IF | 1 |
| White, M | 1 |
| Marino, JL | 1 |
| Peate, M | 1 |
| Basson, R | 5 |
| Sauer, U | 1 |
| Talaulikar, V | 1 |
| Davies, MC | 1 |
| O'Loughlin, JI | 1 |
| Weinberg, J | 1 |
| Young, AH | 1 |
| Bodnar, T | 1 |
| Brotto, LA | 1 |
| Davis, SR | 4 |
| Pluchino, N | 1 |
| Carmignani, A | 1 |
| Cubeddu, A | 1 |
| Santoro, A | 1 |
| Cela, V | 1 |
| Errasti, T | 1 |
| Alcalà, TE | 1 |
| Bertin, J | 1 |
| Dury, AY | 1 |
| Ouellet, J | 2 |
| Pelletier, G | 2 |
| Labrie, F | 4 |
| Zimmerman, Y | 1 |
| Foidart, JM | 1 |
| Pintiaux, A | 1 |
| Minon, JM | 1 |
| Fauser, BC | 1 |
| Cobey, K | 1 |
| Coelingh Bennink, HJ | 1 |
| Eden, JA | 1 |
| Bouchard, C | 1 |
| Derogatis, L | 1 |
| Girard, G | 1 |
| Ayotte, N | 1 |
| Gallagher, J | 1 |
| Cusan, L | 1 |
| Archer, DF | 1 |
| Portman, D | 1 |
| Lavoie, L | 1 |
| Beauregard, A | 1 |
| Côté, I | 1 |
| Martel, C | 2 |
| Vaillancourt, M | 1 |
| Balser, J | 1 |
| Moyneur, E | 1 |
| Worsley, R | 1 |
| Miller, KK | 1 |
| Parish, SJ | 1 |
| Santoro, N | 1 |
| Farmer, M | 1 |
| Yoon, H | 1 |
| Goldstein, I | 1 |
| Peixoto, C | 1 |
| Carrilho, CG | 1 |
| Barros, JA | 1 |
| Ribeiro, TT | 1 |
| Silva, LM | 1 |
| Nardi, AE | 1 |
| Cardoso, A | 1 |
| Veras, AB | 1 |
| Panjari, M | 2 |
| Bell, R | 1 |
| Adams, J | 1 |
| Morrow, C | 1 |
| Papalia, MA | 2 |
| Astbury, J | 1 |
| Morales, A | 1 |
| Black, A | 1 |
| Emerson, L | 1 |
| Barkin, J | 1 |
| Kuzmarov, I | 1 |
| Day, A | 1 |
| Wierman, ME | 1 |
| van Lankveld, J | 1 |
| Brotto, L | 1 |
| Simon, JA | 1 |
| Tan, O | 1 |
| Bradshaw, K | 1 |
| Carr, BR | 1 |
| Maggi, M | 1 |
| Buvat, J | 2 |
| Corona, G | 1 |
| Guay, A | 2 |
| Torres, LO | 1 |
| Kokot-Kierepa, M | 1 |
| Bartuzi, A | 1 |
| Kulik-Rechberger, B | 1 |
| Rechberger, T | 1 |
| Belaisch, J | 1 |
| Johnson, CE | 1 |
| Berman, JR | 1 |
| Burger, H | 1 |
| Saltzman, E | 1 |
| Bachmann, G | 1 |
| Oza, D | 1 |
| Bácsi, K | 1 |
| Kósa, J | 1 |
| Lazáry, A | 1 |
| Horváth, H | 1 |
| Balla, B | 1 |
| Lakatos, P | 1 |
| Speer, G | 1 |
| Abrahamsson, L | 1 |
| Hackl, H | 1 |
| Orstam, S | 1 |
| Lafisca, S | 1 |
| Bolelli, G | 1 |
| Franceschetti, F | 1 |
| Filicori, M | 1 |
| Flamigni, C | 1 |
| Marigo, M | 1 |
| Sutcliffe, RG | 1 |
| Russell, AJ | 1 |
| Edwards, CR | 1 |
| Wallace, AM | 1 |
| Herzog, AG | 1 |
| Seibel, MM | 1 |
| Schomer, DL | 1 |
| Vaitukaitis, JL | 1 |
| Geschwind, N | 1 |
| Neri, A | 1 |
| Zukerman, Z | 1 |
| Aygen, M | 1 |
| Lidor, Y | 1 |
| Kaufman, H | 1 |
| Bannister, P | 1 |
| Oakes, J | 1 |
| Sheridan, P | 1 |
| Losowsky, MS | 1 |
| Borghi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label Vulvoscopy Photography Study of Changes in Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Administration of 6.5 Mg Vaginal Prasterone in Menopausal Women With Moderate to Severe Dyspareunia[NCT03568604] | Phase 4 | 18 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| DHEA Against Vaginal Atrophy - Safety Study of 12 Months[NCT01256671] | Phase 3 | 530 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)[NCT03619005] | Phase 3 | 0 participants (Actual) | Interventional | 2018-11-13 | Withdrawn (stopped due to Business decision to not continue this study (only few subjects were screened).) | ||
| Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)[NCT03287232] | Phase 3 | 653 participants (Actual) | Interventional | 2017-10-16 | Completed | ||
| Thermal Treatment of Vulvo-vaginal Atrophy (VVA) Using Novel Low-energy Dynamic Quadripolar Radio-Frequency (DQRF)[NCT03857893] | 53 participants (Actual) | Interventional | 2019-03-01 | Terminated (stopped due to The study was delayed due to the Covid 19 pandemic. The study was stopped prematurely due to a lack of efficiency (reported by the patients)) | |||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.[NCT00398034] | Phase 2 | 0 participants (Actual) | Interventional | 2006-10-30 | Withdrawn (stopped due to The original PI (David Siegel) Left the VA) | ||
| Effect of Type and Severity of Liver Cirrhosis on Semen Parameters and Reproductive Hormones[NCT03167749] | 90 participants (Anticipated) | Observational | 2018-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The severity of dyspareunia was evaluated by a questionnaire. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup MS | Week 52: Subgroup MS | Change from Baseline: Subgroup MS | Baseline: Subgroup MBS/MS | Week 52: Subgroup MBS/MS | Change from Baseline: Subgroup MBS/MS | |
| 0.50% DHEA | 2.53 | 0.85 | -1.68 | 2.57 | 0.87 | -1.69 |
The severity of irritation/itching was evaluated by a questionnaire. The severity of irritation/itching recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup MS | Week 52: Subgroup MS | Change from Baseline: Subgroup MS | Baseline: Subgroup MBS/MS | Week 52: Subgroup MBS/MS | Change from Baseline: Subgroup MBS/MS | |
| 0.50% DHEA | 2.10 | 0.60 | -1.50 | 2.13 | 0.74 | -1.39 |
The severity of vaginal dryness was evaluated by a questionnaire. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup MS | Week 52: Subgroup MS | Change from Baseline: Subgroup MS | Baseline: Subgroup MBS/MS | Week 52: Subgroup MBS/MS | Change from Baseline: Subgroup MBS/MS | |
| 0.50% DHEA | 2.22 | 0.59 | -1.63 | 2.19 | 0.67 | -1.52 |
The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | percentage of parabasal cells (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup ALL | Week 52: Subgroup ALL | Change from Baseline: Subgroup ALL | Baseline: Subgroup VVA | Week 52: Subgroup VVA | Change from Baseline: Subgroup VVA | |
| 0.50% DHEA | 55.49 | 12.81 | -42.67 | 63.95 | 14.80 | -49.14 |
The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | percentage of superficial cells (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup ALL | Week 52: Subgroup ALL | Change from Baseline: Subgroup ALL | Baseline: Subgroup VVA | Week 52: Subgroup VVA | Change from Baseline: Subgroup VVA | |
| 0.50% DHEA | 2.02 | 9.42 | 7.41 | 0.96 | 8.81 | 7.85 |
A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | pH (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup ALL | Week 52: Subgroup ALL | Change from Baseline: Subgroup ALL | Baseline: Subgroup VVA | Week 52: Subgroup VVA | Change from Baseline: Subgroup VVA | |
| 0.50% DHEA | 6.23 | 5.09 | -1.14 | 6.40 | 5.13 | -1.27 |
The long-term safety of intravaginal prasterone has been evaluated on different parameters including the endometrium. For this purpose, endometrial biopsies were performed at screening and at the end of the study (52 weeks) or at discontinuation visit for women who were exposed to intravaginal DHEA (prasterone) for at least 12 weeks. At screening, the endometrium had to be atrophic/inactive for women to be enrolled in the study. Only the end-of-study data are presented. (NCT01256671)
Timeframe: Baseline and Week 52 (or discontinuation)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Endometrium: Atrophic/Inactive | Endometrium: No/Insufficient Tissue for Diagnosis | |
| 0.50% DHEA | 421 | 36 |
The long-term safety of intravaginal prasterone has been evaluated on different parameters including the serum levels of DHEA and its metabolites. For this purpose, blood samples were collected at Baseline and different post-Baseline timepoints for the determination of serum steroid levels by a central laboratory using validated liquid chromatography tandem mass spectrometry (LC-MS/MS) methods. The serum levels of dehydroepiandrosterone (DHEA), estradiol (E2) and testosterone (TESTO) obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | pg/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| DHEA: Baseline | DHEA: Week 52 | DHEA: Change from Baseline | E2: Baseline | E2: Week 52 | E2: Change from Baseline | TESTO: Baseline | TESTO: Week 52 | TESTO: Change from Baseline | |
| 0.50% DHEA | 2071.61 | 2997.25 | 925.65 | 6.05 | 4.46 | -1.59 | 161.28 | 189.44 | 28.17 |
20 reviews available for dehydroepiandrosterone and Sex Disorders
| Article | Year |
|---|---|
Efficacy of interventions to manage sexual dysfunction in women with cancer: a systematic review.
Topics: Cancer Survivors; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Male; Neoplasms; Randomized C | 2022 |
Sexual Dysfunctions in Women: Are Androgens at Fault?
Topics: Androgens; Dehydroepiandrosterone; Female; Humans; Libido; Sexual Dysfunction, Physiological; Sexual | 2021 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase.
Topics: Administration, Intravaginal; Dehydroepiandrosterone; Female; Humans; Perimenopause; Postmenopause; | 2018 |
Androgen use for low sexual desire in midlife women.
Topics: Androgens; Dehydroepiandrosterone; Female; Humans; Menopause; Middle Aged; Sex Hormone-Binding Globu | 2013 |
Androgen therapy in women: for whom and when.
Topics: Aging; Androgens; Dehydroepiandrosterone; Female; Hormone Replacement Therapy; Humans; Hypogonadism; | 2013 |
Androgens and Female Sexual Function and Dysfunction--Findings From the Fourth International Consultation of Sexual Medicine.
Topics: Adult; Androgens; Consensus Development Conferences as Topic; Dehydroepiandrosterone; Female; Hormon | 2016 |
Future Targets for Female Sexual Dysfunction.
Topics: Alprostadil; Anxiety; Aphrodisiacs; Apomorphine; Consensus; Dehydroepiandrosterone; Dopamine; Dopami | 2016 |
The effects of dehydroepiandrosterone on sexual function: a systematic review.
Topics: Dehydroepiandrosterone; Female; Humans; Libido; Middle Aged; Postmenopause; Quality of Life; Sexual | 2017 |
DHEA for postmenopausal women: a review of the evidence.
Topics: Carbohydrate Metabolism; Dehydroepiandrosterone; Female; Humans; Lipid Metabolism; Postmenopause; Se | 2010 |
Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Breast Neoplasms; Complementa | 2012 |
Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA).
Topics: Acromegaly; Adrenal Insufficiency; Dehydroepiandrosterone; Gonadotropins; Hormone Replacement Therap | 2013 |
[Local estrogen therapy--clinical implications--2012 update].
Topics: Dehydroepiandrosterone; Estrogen Replacement Therapy; Estrogens; Female; Humans; Poland; Postmenopau | 2012 |
[DHEA: desire and resistance].
Topics: Aged; Aging; Breast Neoplasms; Dehydroepiandrosterone; Erectile Dysfunction; Female; Humans; Libido; | 2002 |
Androgen therapy with dehydroepiandrosterone.
Topics: Adjuvants, Immunologic; Adrenal Insufficiency; Aged; Aging; Cardiovascular Diseases; Cognition; Dehy | 2003 |
The role of androgens in hormone replacement therapy.
Topics: Adult; Age Factors; Aged; Androgens; Breast Neoplasms; Cardiovascular System; Dehydroepiandrosterone | 2005 |
Clinical practice. Sexual desire and arousal disorders in women.
Topics: Combined Modality Therapy; Dehydroepiandrosterone; Estrogens; Female; Humans; Middle Aged; Practice | 2006 |
Clinical evaluation of women presenting with low libido and determination of whether androgen therapy might be appropriate.
Topics: Androgens; Dehydroepiandrosterone; Female; Humans; Libido; Norpregnenes; Sexual Dysfunction, Physiol | 2006 |
Dehydroepiandrosterone therapy as female androgen replacement.
Topics: Adrenal Insufficiency; Aging; Androgens; Dehydroepiandrosterone; Female; Hormone Replacement Therapy | 2006 |
Female androgen insufficiency.
Topics: Adrenal Glands; Aging; Algorithms; Androgens; Dehydroepiandrosterone; Female; Humans; Libido; Ovarie | 2006 |
[Significance of dehydroepiandrosterone and dehydroepiandrosterone sulfate in different diseases].
Topics: Androgens; Cardiovascular Diseases; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Diabetes | 2007 |
3 trials available for dehydroepiandrosterone and Sex Disorders
| Article | Year |
|---|---|
Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects.
Topics: Acne Vulgaris; Adolescent; Adult; Androgen Antagonists; Androstenes; Belgium; Contraceptives, Oral, | 2015 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Female; Huma | 2016 |
Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency.
Topics: Aged; Androgens; Dehydroepiandrosterone; Double-Blind Method; Humans; Male; Middle Aged; Outcome Ass | 2009 |
16 other studies available for dehydroepiandrosterone and Sex Disorders
| Article | Year |
|---|---|
Dehydroepiandrosterone and cortisol as markers of HPA axis dysregulation in women with low sexual desire.
Topics: Adult; Biomarkers; Circadian Rhythm; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Hypotha | 2019 |
Localization of the androgen-synthesizing enzymes, androgen receptor, and sex steroids in the vagina: possible implications for the treatment of postmenopausal sexual dysfunction.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgens; Animals; Dehydro | 2014 |
Intracrinology in action: importance of extragonadal sex steroid biosynthesis and inactivation in peripheral tissues in both women and men.
Topics: Androgens; Atrophic Vaginitis; Clinical Trials as Topic; Dehydroepiandrosterone; Endocrinology; Estr | 2015 |
DHEA replacement for postmenopausal women: placebo or panacea?
Topics: Administration, Intravaginal; Administration, Oral; Aged; Aging; Cognition Disorders; Dehydroepiandr | 2015 |
Methodology and challenges to recruitment to a randomized, double-blind, placebo-controlled trial of oral DHEA in postmenopausal women.
Topics: Aged; Australia; Dehydroepiandrosterone; Double-Blind Method; Female; Health Knowledge, Attitudes, P | 2008 |
Summary of the recommendations on sexual dysfunctions in women.
Topics: Adjuvants, Immunologic; Dehydroepiandrosterone; Diagnostic and Statistical Manual of Mental Disorder | 2010 |
Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen.
Topics: Administration, Intravaginal; Aged; Breast Neoplasms; Dehydroepiandrosterone; Dosage Forms; Endometr | 2011 |
Effects of ovariectomy and dehydroepiandrosterone (DHEA) on vaginal wall thickness and innervation.
Topics: Administration, Intravaginal; Animals; Dehydroepiandrosterone; Female; Mucous Membrane; Ovariectomy; | 2012 |
Female sexual dysfunction in hypopituitarism.
Topics: Dehydroepiandrosterone; Female; Humans; Hypopituitarism; Libido; Postmenopause; Sexual Dysfunction, | 2007 |
[Non-virilizing hormonal therapy in women with secondary disorders of sexual responsiveness].
Topics: Adult; Clomiphene; Contraceptives, Oral, Combined; Dehydroepiandrosterone; Drug Combinations; Estrad | 1983 |
Hormone levels in methadone-treated drug addicts.
Topics: Adolescent; Adult; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradio | 1981 |
Human 3 beta-hydroxysteroid dehydrogenase: genes and phenotypes.
Topics: 3-Hydroxysteroid Dehydrogenases; Dehydroepiandrosterone; Hirsutism; Humans; Mutation; Phenotype; Pol | 1996 |
Reproductive endocrine disorders in women with partial seizures of temporal lobe origin.
Topics: Adult; Dehydroepiandrosterone; Endocrine System Diseases; Epilepsy, Temporal Lobe; Estradiol; Female | 1986 |
The effect of long-term administration of digoxin on plasma androgens and sexual dysfunction.
Topics: Adult; Androgens; Androstenedione; Dehydroepiandrosterone; Digoxin; Erectile Dysfunction; Humans; Li | 1987 |
Sex hormone changes in chronic liver disease: a matched study of alcoholic versus non-alcoholic liver disease.
Topics: Adult; Aged; Androstenedione; Dehydroepiandrosterone; Estradiol; Gonadal Steroid Hormones; Humans; L | 1987 |
[Sexual changes in the adult male connected with hyperproduction of dehydroepiandrosterone at the adrenal gland level].
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adrenal Glands; Adult; Dehydroepiandrosterone; Female; Gyn | 1973 |